Market Cap 57.49B
Revenue (ttm) 21.84B
Net Income (ttm) 1.68B
EPS (ttm) N/A
PE Ratio 14.29
Forward PE 13.88
Profit Margin 7.68%
Debt to Equity Ratio 0.69
Volume 3,433,200
Avg Vol 2,016,268
Day's Range N/A - N/A
Shares Out 284.91M
Stochastic %K 45%
Beta 0.23
Analysts Sell
Price Target $203.90

Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 201 847 6800
Website: www.bd.com
Address:
1 Becton Drive, Franklin Lakes, United States
catacal_
catacal_ Jan. 23 at 7:56 PM
$BDX - 2026 Annual Meeting of Shareholders on Tue. Jan. 27 at 1:00 PM. Could be significant. $QQQ
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 23 at 7:24 PM
1 · Reply
Guntz
Guntz Jan. 23 at 3:34 PM
$BDX What happened here?
1 · Reply
ZacksResearch
ZacksResearch Jan. 23 at 6:00 AM
FDA green light for BD — a new medtech catalyst in play 👀🩺 $BDX secured FDA 510(k) clearance for its EnCor EnCompass breast biopsy system, with an early 2026 launch planned to enhance procedural flexibility and patient care. See why this approval matters for BD 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-teaser-29977&ADID=SYND_STOCKTWITS_TWEET_2_2820556_TEASER_29977
0 · Reply
ZacksResearch
ZacksResearch Jan. 22 at 7:18 PM
$BDX is doubling down on biologics — and this move looks strategic. 🚀 BD is expanding its Ypsomed partnership with a 5.5 mL Neopak XtraFlow syringe, directly targeting rising demand for large-volume subcutaneous self-injection in the growing biologics market. See why this partnership expansion matters 👉 https://www.zacks.com/stock/news/2821310/bd-and-ypsomed-expand-partnership-to-target-growing-biologics-market?cid=sm-stocktwits-2-2821310-teaser-30142&ADID=SYND_STOCKTWITS_TWEET_2_2821310_TEASER_30142
0 · Reply
ZacksResearch
ZacksResearch Jan. 22 at 6:18 PM
$BDX expands partnership with Ypsomed — what it means for investors! 🤝 BDX shares rose 1.4% as it announced the expansion of its partnership with Ypsomed to include a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe, aligning with Ypsomed’s autoinjector. This move positions BD to capture growth in the biologics market, with samples expected by mid-2026. 📈 Discover the full impact here 👉 https://www.zacks.com/stock/news/2821310/bd-and-ypsomed-expand-partnership-to-target-growing-biologics-market?cid=sm-stocktwits-2-2821310-body-30127&ADID=SYND_STOCKTWITS_TWEET_2_2821310_BODY_30127
0 · Reply
ZacksResearch
ZacksResearch Jan. 22 at 6:00 AM
$BDX receives FDA clearance for innovative breast biopsy system — what's next for the stock? 🤔 The EnCor EnCompass system offers multi-modality use and advanced features, strengthening BD's leadership in women’s health diagnostics. But shares have dipped 2.4% since the announcement. 📉 Opportunity assessment here 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-body-29968&ADID=SYND_STOCKTWITS_TWEET_2_2820556_BODY_29968
0 · Reply
ZacksResearch
ZacksResearch Jan. 21 at 7:15 PM
$BDX just cleared a key regulatory hurdle — and it matters for what’s next. ✅ BD received FDA 510(k) approval for its EnCor EnCompass breast biopsy system, with an early 2026 launch planned to enhance procedural flexibility and patient care. Incremental innovation with real clinical impact. Get the full details here 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-teaser-29967&ADID=SYND_STOCKTWITS_TWEET_2_2820556_TEASER_29967
0 · Reply
ZacksResearch
ZacksResearch Jan. 21 at 6:15 PM
$BDX just got FDA clearance for an advanced breast biopsy system! 🚀 The EnCor EnCompass System, launching in 2026, promises multi-modality use and precision that could strengthen BDX's leadership in women's health diagnostics. Discover how this could support BDX's long-term growth strategy 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-body-29964&ADID=SYND_STOCKTWITS_TWEET_2_2820556_BODY_29964
0 · Reply
TalkMarkets
TalkMarkets Jan. 18 at 3:57 PM
3 Top #Dividend #Stocks For 2026 $BDX $CTAS $NDSN https://talkmarkets.com/content/stocks--equities/3-top-dividend-stocks-for-2026?post=550859
0 · Reply
Latest News on BDX
MoneyShow's Best Investment Ideas For 2026: Part 2

Jan 12, 2026, 4:20 PM EST - 12 days ago

MoneyShow's Best Investment Ideas For 2026: Part 2

AXSM BRO BX CALM


BD To Host Virtual 2026 Annual Meeting of Shareholders

Jan 12, 2026, 4:15 PM EST - 12 days ago

BD To Host Virtual 2026 Annual Meeting of Shareholders


Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 25 days ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR


Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 4 weeks ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BKH


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 2 months ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


BD Board Increases Dividend for 54th Consecutive Year

Nov 6, 2025, 6:25 AM EST - 2 months ago

BD Board Increases Dividend for 54th Consecutive Year


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 3 months ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 3 months ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BKH


Becton Dickinson's CFO to depart

Oct 15, 2025, 4:42 PM EDT - 3 months ago

Becton Dickinson's CFO to depart


BD Announces CFO Transition Plan

Oct 15, 2025, 4:15 PM EDT - 3 months ago

BD Announces CFO Transition Plan


Best Dividend Aristocrats For October 2025

Sep 28, 2025, 1:00 AM EDT - 4 months ago

Best Dividend Aristocrats For October 2025

ABT ADP ATO BEN CAH CHRW CL


catacal_
catacal_ Jan. 23 at 7:56 PM
$BDX - 2026 Annual Meeting of Shareholders on Tue. Jan. 27 at 1:00 PM. Could be significant. $QQQ
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 23 at 7:24 PM
1 · Reply
Guntz
Guntz Jan. 23 at 3:34 PM
$BDX What happened here?
1 · Reply
ZacksResearch
ZacksResearch Jan. 23 at 6:00 AM
FDA green light for BD — a new medtech catalyst in play 👀🩺 $BDX secured FDA 510(k) clearance for its EnCor EnCompass breast biopsy system, with an early 2026 launch planned to enhance procedural flexibility and patient care. See why this approval matters for BD 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-teaser-29977&ADID=SYND_STOCKTWITS_TWEET_2_2820556_TEASER_29977
0 · Reply
ZacksResearch
ZacksResearch Jan. 22 at 7:18 PM
$BDX is doubling down on biologics — and this move looks strategic. 🚀 BD is expanding its Ypsomed partnership with a 5.5 mL Neopak XtraFlow syringe, directly targeting rising demand for large-volume subcutaneous self-injection in the growing biologics market. See why this partnership expansion matters 👉 https://www.zacks.com/stock/news/2821310/bd-and-ypsomed-expand-partnership-to-target-growing-biologics-market?cid=sm-stocktwits-2-2821310-teaser-30142&ADID=SYND_STOCKTWITS_TWEET_2_2821310_TEASER_30142
0 · Reply
ZacksResearch
ZacksResearch Jan. 22 at 6:18 PM
$BDX expands partnership with Ypsomed — what it means for investors! 🤝 BDX shares rose 1.4% as it announced the expansion of its partnership with Ypsomed to include a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe, aligning with Ypsomed’s autoinjector. This move positions BD to capture growth in the biologics market, with samples expected by mid-2026. 📈 Discover the full impact here 👉 https://www.zacks.com/stock/news/2821310/bd-and-ypsomed-expand-partnership-to-target-growing-biologics-market?cid=sm-stocktwits-2-2821310-body-30127&ADID=SYND_STOCKTWITS_TWEET_2_2821310_BODY_30127
0 · Reply
ZacksResearch
ZacksResearch Jan. 22 at 6:00 AM
$BDX receives FDA clearance for innovative breast biopsy system — what's next for the stock? 🤔 The EnCor EnCompass system offers multi-modality use and advanced features, strengthening BD's leadership in women’s health diagnostics. But shares have dipped 2.4% since the announcement. 📉 Opportunity assessment here 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-body-29968&ADID=SYND_STOCKTWITS_TWEET_2_2820556_BODY_29968
0 · Reply
ZacksResearch
ZacksResearch Jan. 21 at 7:15 PM
$BDX just cleared a key regulatory hurdle — and it matters for what’s next. ✅ BD received FDA 510(k) approval for its EnCor EnCompass breast biopsy system, with an early 2026 launch planned to enhance procedural flexibility and patient care. Incremental innovation with real clinical impact. Get the full details here 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-teaser-29967&ADID=SYND_STOCKTWITS_TWEET_2_2820556_TEASER_29967
0 · Reply
ZacksResearch
ZacksResearch Jan. 21 at 6:15 PM
$BDX just got FDA clearance for an advanced breast biopsy system! 🚀 The EnCor EnCompass System, launching in 2026, promises multi-modality use and precision that could strengthen BDX's leadership in women's health diagnostics. Discover how this could support BDX's long-term growth strategy 👉 https://www.zacks.com/stock/news/2820556/bd-gets-fda-510k-approval-for-encor-encompass-breast-biopsy-system?cid=sm-stocktwits-2-2820556-body-29964&ADID=SYND_STOCKTWITS_TWEET_2_2820556_BODY_29964
0 · Reply
TalkMarkets
TalkMarkets Jan. 18 at 3:57 PM
3 Top #Dividend #Stocks For 2026 $BDX $CTAS $NDSN https://talkmarkets.com/content/stocks--equities/3-top-dividend-stocks-for-2026?post=550859
0 · Reply
COYOTEofWS
COYOTEofWS Jan. 15 at 11:29 PM
$BDX if this can get above $210 it should be fairly clear to push on up to 230. GLTA ✌️
0 · Reply
JFDI
JFDI Jan. 14 at 7:35 PM
$BDX ..
0 · Reply
DividendPower
DividendPower Jan. 14 at 2:49 PM
3 Top Dividend Stocks For 2026 https://www.dividendpower.org/top-dividend-stocks-2026/ $BDX $NDSN $CTAS @SureDividend
0 · Reply
11thestate
11thestate Jan. 14 at 1:53 PM
$BDX has agreed to settle with investors over claims that it misled them about the functionality, safety, and regulatory risks of its Alaris infusion pump system. Who’s eligible? Anyone who purchased $BDX shares between November 5, 2019 and February 5, 2020. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $2.14 — but if only ~25% of eligible investors file, the effective payout could increase to $8.56. Can I still file? Yes — late claims are being considered, subject to court approval. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 14 at 3:23 AM
$BDX Share Price: $201.48 Contract Selected: Jun 18, 2026 $200 Calls Buy Zone: $10.88 – $13.44 Target Zone: $20.16 – $24.63 Potential Upside: 75% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 13 at 5:51 PM
$BDX Current Stock Price: $200.54 Contracts to trade: $200 BDX Jan 16 2026 Call Entry: $2.90 Exit: $5.10 ROI: 76% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
StockConsultant
StockConsultant Jan. 7 at 3:51 AM
$BDX Becton Dickinson stock, nice rally off the 195.82 support area and breakout
0 · Reply
11thestate
11thestate Jan. 2 at 3:03 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BDX — how you can actually recover something: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
TalkMarkets
TalkMarkets Jan. 2 at 12:15 PM
Dividend Stock Analysis - Becton, Dickinson And Co. $BDX https://talkmarkets.com/content/stocks--equities/dividend-stock-analysis-becton-dickinson-and-co?post=547929&userid=166882
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 1 at 5:16 PM
$BDX Significant decrease in volume compared to average volume. Price has been relatively stable around $195 levels with no major price movements. Waiting for a lower H% before considering any entry.
0 · Reply
TalkMarkets
TalkMarkets Jan. 1 at 1:44 PM
10 Best Dividend Stocks For 2026 $BRO $LAD $THG $BDX $SON https://talkmarkets.com/content/stocks--equities/10-best-dividend-stocks-for-2026?post=547774&userid=166882
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 11:09 PM
$BDX Current Stock Price: $196.38 Contracts to trade: $195 BDX Jan 16 2026 Call Entry: $4.00 Exit: $5.21 ROI: 30% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply